Publications by authors named "Denise Bellman"

Claim this Profile
E
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Rebecca A Marsh, Marepalli B Rao, Aharon Gefen, Denise Bellman, Parinda A Mehta

Biol Blood Marrow Transplant· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Rebecca A Marsh, Mi-Ok Kim, Chunyan Liu, Denise Bellman, Laura Hart

Biol Blood Marrow Transplant· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis